Abstract | AIM: METHODS: Twenty-one patients were treated with a placebo and ABT-229 (2.5, 5 or 10 mg b.d.) in a randomized, incomplete crossover study design. Ambulatory 24-h pH manometry was performed and gastric emptying was assessed by the 13C-octanoic acid breath test on the seventh day of treatment. RESULTS: A significant decrease was found in the mean (+/- s.e.) percentage of reflux time (intra-oesophageal pH < 4) for ABT-229 5 mg b.d. and 10 mg b.d., but not for 2.5 mg b.d., compared with placebo. For ABT-229 5 mg, it was 8.5 +/- 0.5% vs. 10.7 +/- 0.7% (P < 0.038) and, for ABT-229 10 mg, it was 6.6 +/- 0.5% vs. 8.4 +/- 0.5% (P < 0.019). There were no significant differences in any of the analysed manometric parameters. In addition, the gastric half-emptying time for all doses of ABT-229 did not differ significantly from that after placebo. CONCLUSIONS:
ABT-229 is able to reduce slightly, but significantly, acid reflux in patients with gastro-oesophageal reflux disease. This effect does not appear to be due to a measurable improvement in oesophageal motility or gastric emptying.
|
Authors | P Netzer, B Schmitt, W Inauen |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 16
Issue 8
Pg. 1481-90
(Aug 2002)
ISSN: 0269-2813 [Print] England |
PMID | 12182748
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Gastrointestinal Agents
- Motilin
- Alemcinal
- Erythromycin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Cross-Over Studies
- Dose-Response Relationship, Drug
- Double-Blind Method
- Erythromycin
(analogs & derivatives, therapeutic use)
- Female
- Gastric Emptying
(drug effects)
- Gastroesophageal Reflux
(drug therapy, physiopathology)
- Gastrointestinal Agents
(therapeutic use)
- Gastrointestinal Motility
(drug effects)
- Humans
- Hydrogen-Ion Concentration
(drug effects)
- Male
- Manometry
(methods)
- Middle Aged
- Motilin
(agonists)
|